Pacific Biosciences Of California (PACB) Liabilities and Shareholders Equity (2010 - 2026)

Pacific Biosciences Of California has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $782.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 9.11% year-over-year to $782.4 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 billion (down 37.11% YoY), and the FY2025 full-year result was $784.1 million, down 37.79% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $782.4 million, roughly flat from $784.1 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.9 billion in Q1 2022, with the low at $782.4 million in Q1 2026.
• Average Liabilities and Shareholders Equity over 5 years is $1.5 billion, with a median of $1.7 billion recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity jumped 54.58% in 2022 and plunged 48.45% in 2025.
• Tracing PACB's Liabilities and Shareholders Equity over 5 years: stood at $1.8 billion in 2022, then decreased by 1.19% to $1.7 billion in 2023, then retreated by 27.81% to $1.3 billion in 2024, then sank by 37.79% to $784.1 million in 2025, then declined by 0.22% to $782.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $782.4 million (Q1 2026), $784.1 million (Q4 2025), and $803.2 million (Q3 2025), per Business Quant data.

Peer Comparison